October 25, 2014
The Human Rights Campaign has endorsed the use of emtricitabine plus tenofovir disoproxil fumarate for pre-exposure prophylaxis, according to an HRC policy paper.
Emtricitabine/tenofovir disoproxil fumarate (Truvada, Gilead Sciences) previously had been supported by the CDC and WHO, as well as AIDS United and the Gay Men’s Health Crisis Center. The HRC is the largest civil rights organization for lesbian, gay, bisexual and transgender individuals, the demographics most at risk for HIV infection. Currently, Truvada is the only brand name anti-HIV treatment approved for PrEP, according to a related press release.